Drug Manufacturers - Specialty & Generic | Healthcare
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is headquartered in Manimajra, India.
Market Cap
6591698944
Current Price
108.74
52 Week Range
68.72 - 186.0
Previous Close
95.94
Open
96.4
Sector
Healthcare
Address
Shivalik Enclave, SCO 850 NAC, Manimajra, 160101, India
Phone
+91-17250-61850
Fax
+91-17227-30504
Website
https://www.indswiftlabs.com
Day Low
96.37
Day High
109.5
Dividend Yield
PE Ratio
1.7837926
Earnings Per Share
60.96
Beta
0.303
EBITDA
914329472
Book Value
171.283
EPS
Name | Title | Age | Year Born |
---|---|---|---|
Mr. Navrattan R. Munjal | Chairman & MD | 72 | 1952 |
Mr. Himanshu Jain BCom | Joint MD & Whole Time Director | 42 | 1982 |
Mr. Rishav Mehta | Executive Director | 33 | 1991 |
Mr. Sahil Munjal | Executive Director | 44 | 1980 |
Mr. Gagan Aggarwal | Chief Financial Officer | - | - |
Ashok Kothari | General Manager of Information & Technology | - | - |
Mr. Pardeep Verma | VP of Corporate Affairs, Compliance Officer & Company Secretary | - | - |
Varun Chhabra | Senior Vice President of Marketing | - | - |
Akashdeep Sharma | Group HR Head | - | - |
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Healthcare • Drug Manufacturers - Specialty & Generic
Find high-momentum stocks with strong forward PE ratios and moderate volatility for aggressive investors.
Explore stocks with high dividend yields and low debt-to-equity ratios for stable income.
Discover large-cap stocks with stable beta for lower volatility and reliable returns.
Find undervalued stocks with reasonable forward PE and market cap for value investors.
Discover stocks with strong 5-year revenue growth trading near their 52-week lows, ideal for long-term investment.
Explore high-beta stocks with significant price movement potential for risk-tolerant investors.
Discover mid to large-cap stocks with strong growth potential and attractive valuations.
Find affordable stocks with consistent dividend payouts for income-focused investors.